1.
|
D CilloniE GottardiM FavaUsefulness of
quantitative assessment of the WT1 gene transcript as a marker for
minimal residual disease
detectionBlood102773774200310.1182/blood-2003-03-098012835231
|
2.
|
KM CallT GlaserCY ItoIsolation and
characterization of a zinc finger polypeptide gene at the human
chromosome-11 Wilms’ tumor locusCell6050952019902154335
|
3.
|
V ScharnhorstAJ van der EbAG JochemsenWT1
proteins: functions in growth and
differentiationGene273141161200110.1016/S0378-1119(01)00593-511595161
|
4.
|
AL MenkeA SchedlWT1 and glomerular
functionSemin Cell Dev
Biol14233240200310.1016/S1084-9521(03)00026-014627122
|
5.
|
GB SilbersteinHK VanP StricklandCT Roberts
JrCW DanielAltered expression of the WT1 Wilms tumor suppressor
gene in human breast cancerProc Natl Acad Sci
USA9481328137199710.1073/pnas.94.15.81329223327
|
6.
|
A MakrigiannakisK AminG CoukosJL TillyC
CoutifarisRegulated expression and potential roles of p53 and
Wilms’ tumor suppressor gene (WT1) during follicular development in
the human ovaryJ Clin Endocrinol Metab854494592000
|
7.
|
S NakatsukaY OjiT
HoriuchiImmunohistochemical detection of WT1 protein in a variety
of cancer cellsMod Pathol19804814200616547468
|
8.
|
H MiwaM BeranGF SaundersExpression of the
Wilms-Tumor Gene (Wt1) in human
leukemiasLeukemia640540919921317488
|
9.
|
HD MenssenHJ RenklU RodeckPresence of
Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in
the majority of human acute leukemiasLeukemia9106010671995
|
10.
|
K InoueH OgawaT YamagamiLong-term
follow-up of minimal residual disease in leukemia patients by
monitoring WT1 (Wilms tumor gene) expression
levelsBlood882267227819968822948
|
11.
|
H SugiyamaWilms tumor gene (WT1) as a new
marker for the detection of minimal residual disease in
leukemiaLeuk Lymphoma30556119989669676
|
12.
|
J TrkaM KalinovaO HrusakReal-time
quantitative PCR detection of WT1 gene expression in children with
AML: prognostic significance, correlation with disease status and
residual disease detection by flow
cytometryLeukemia1613811389200210.1038/sj.leu.240251212094264
|
13.
|
H OgawaH TamakiK IkegameThe usefulness of
monitoring WT1 gene transcripts for the prediction and management
of relapse following allogeneic stem cell transplantation in acute
type
leukemiaBlood10116981704200310.1182/blood-2002-06-183112406915
|
14.
|
M GargH MooreK TobalJAL YinPrognostic
significance of quantitative analysis of WT1 gene transcripts by
competitive reverse transcription polymerase chain reaction in
acute leukaemiaBr J
Haematol1234959200310.1046/j.1365-2141.2003.04552.x
|
15.
|
M OstergaardLH OlesenH HasleE KjeldsenP
HoklandWT1 gene expression: an excellent tool for monitoring
minimal residual disease in 70% of acute myeloid leukaemia patients
- results from a single-centre studyBr J
Haematol125590600200415147374
|
16.
|
M WeisserW KernS RauhutC SchochW
HiddemannT HaferlachS SchnittgerPrognostic impact of RT-PCR-based
quantification of WT1 gene expression during MRD monitoring of
acute myeloid
leukemiaLeukemia1914161423200510.1038/sj.leu.240380915920493
|
17.
|
D CilloniE GottardiD De
MicheliQuantitative assessment of WT1 expression by real time
quantitative PCR may be a useful tool for monitoring minimal
residual disease in acute leukemia
patientsLeukemia1621152121200210.1038/sj.leu.240267512357365
|
18.
|
D OsborneL FrostK TobalJAL YinElevated
levels of WT1 transcripts in bone marrow harvests are associated
with a high relapse risk in patients autografted for acute myeloid
leukaemiaBone Marrow
Transplant366770200510.1038/sj.bmt.170499215908982
|
19.
|
A CandoniM TiribelliE
ToffolettiQuantitative assessment of WT1 gene expression after
allogeneic stem cell transplantation is a useful tool for
monitoring minimal residual disease in acute myeloid leukemiaEur J
Haematol826168200910.1111/j.1600-0609.2008.01158.x
|
20.
|
D CilloniF MessaF ArrugaEarly prediction
of treatment outcome in acute myeloid leukemia by measurement of
WT1 transcript levels in peripheral blood samples collected after
chemotherapyHaematologica93921924200810.3324/haematol.12165
|
21.
|
HB OmmenCG NyvoldK BraendstrupRelapse
prediction in acute myeloid leukaemia patients in complete
remission using WT1 as a molecular marker: development of a
mathematical model to predict time from molecular to clinical
relapse and define optimal sampling intervalsBr J
Haematol141782791200810.1111/j.1365-2141.2008.07132.x
|
22.
|
Y SakamotoY MariyaS SasakiWT1 mRNA level
in peripheral blood is a sensitive biomarker for monitoring minimal
residual disease in acute myeloid leukemiaTohoku J Exp
Med219169176200910.1620/tjem.219.16919776535
|
23.
|
P ChomczynskiN SacchiSingle-step method of
RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
extractionAnal
Biochem162156159198710.1016/0003-2697(87)90021-22440339
|
24.
|
J PolákJ MarkovaJ SchwarzJ MaaloufovaZ
VolkovaJ CermakC Haskovec[The use of quantitative assessment of
Wilms tumour gene 1 for monitoring of residual disease in acute
myeloid leukemia patients]Cas Lek Cesk14536422006
|
25.
|
KA KreuzerA SaborowskiJ LupbergerC
AppeltIK NaP Le CoutreCA SchmidtFluorescent 5′-exonuclease assay
for the absolute quantification of Wilms’ tumour gene (WT1) mRNA:
implications for monitoring human leukaemiasBr J
Haematol1143133182001
|
26.
|
D CilloniA RennevilleF HermitteReal-time
quantitative polymerase chain reaction detection of minimal
residual disease by standardized WT1 assay to enhance risk
stratification in acute myeloid leukemia: a European LeukemiaNet
studyJ Clin Oncol2751955201200910.1200/JCO.2009.22.4865
|
27.
|
G GianfaldoniF MannelliV PonzianiG LongoS
BenciniA BosiAM VannucchiEarly reduction of WT1 transcripts during
induction chemotherapy predicts for longer disease free and overall
survival in acute myeloid
leukemiaHaematologica95833836201010.3324/haematol.2009.011908
|